Thiosulfuric Acid

Thiosulfuric Acid

SCHEMBL145183

O=C([O-])O.O=S(O)(O)=S.[Na+]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 1/20 0.44
CA4 P22748 3/20 0.38
FAHD1 Q6P587 1/20 0.38
CA1 P00915 1/20 0.35
CA5A P35218 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
LDHA P00338 1/20 0.32
BLM P54132 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.30
LMNA P02545 1/20 0.30
CASP1 P29466 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiosulfuric Acid SCHEMBL230065 0.90 MEN1 (0.50) MEN1KMT2AALDH1A1TSHRCA4
Thiosulfuric Acid SCHEMBL28268652 0.89 TSHR (0.47) MEN1KMT2AALDH1A1TSHRCA4
Thiosulfuric Acid SCHEMBL4209172 0.86 MEN1 (0.44) MEN1KMT2AALDH1A1TSHRCA4
Thiosulfuric Acid SCHEMBL230064 0.86 MEN1 (0.44) MEN1KMT2AALDH1A1TSHRCA4
Sulfuric Acid SCHEMBL8074036 0.85 TSHR (0.50) MEN1KMT2AALDH1A1TSHRCA4
Sulfuric Acid SCHEMBL28097811 0.85 TSHR (0.50) MEN1KMT2AALDH1A1TSHRCA4
Thiosulfuric Acid SCHEMBL28143283 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1TSHRCA5A
Sulfuric Acid SCHEMBL600964 0.81 TSHR (0.69) MEN1KMT2AALDH1A1TSHRCA4
Sulfuric Acid SCHEMBL29229401 0.81 TSHR (0.47) MEN1KMT2AALDH1A1TSHRCA4
Sulfuric Acid SCHEMBL28110198 0.81 TSHR (0.47) MEN1KMT2AALDH1A1TSHRCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4411737-A POST-TREATMENT WITH SODIUM SULFITE, SODIUM SULFIDE AND SODIUM CARBONATE OWENS-ILLINOIS, INC. (US) 1983-10-25 US claimed
US-20240150367-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2024-05-09 US disclosed
US-11945824-B2 Heterocyclic compounds as anti-viral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-04-02 US disclosed
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 WO disclosed
CN-114026105-B Antibacterial aminoglycoside derivative 卓和药业集团股份有限公司 2023-09-26 CN disclosed
US-20230029252-A1 FUCOSYLATED CHONDROITIN SULFATE OLIGOSACCHARIDE, PREPARATION METHOD THEREFOR, COMPOSITION THEREOF AND USE THEREOF Yantai Dongcheng Biochemicals Co., Ltd (CN) 2023-01-26 US disclosed
US-20230023377-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF JAPAN TOBACCO INC. (JP) 2023-01-26 US disclosed
US-20220227802-A1 ANTIBACTERIAL AMINOGLYCOSIDE DERIVATIVES Zhuohe Pharmaceutical Group Co., Ltd (CN) 2022-07-21 US disclosed
CN-110256469-B Pyrrolobenzodiazepines and conjugates thereof 麦迪穆有限责任公司 2022-05-17 CN disclosed
WO-2022086840-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2022-04-28 WO disclosed
US-20050267134-A1 Non-nucleotide composition and method for inhibiting platelet aggregation INSPIRE PHARMACEUTICALS, INC. 2005-12-01 US disclosed
US-20050159388-A1 Non-nucleotide compositions and method for inhibiting platelet aggregation INSPIRE PHARMACEUTICALS, INC. 2005-07-21 US disclosed
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 US disclosed
WO-2005058841-A2 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2005-06-30 WO disclosed
WO-2005040174-A1 TETRAHYDRO-FURO`3,4-D!DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION INSPIRE PHARMACEUTICALS, INC. (US) 2005-05-06 WO disclosed
WO-2005039590-A1 NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN INSPIRE PHARMACEUTICALS, INC. (US) 2005-05-06 WO disclosed
US-5700365-A Crosslinked polyacrylamide gels with high monomer: crosslinker ratios AMRESCO INC. (US) 1997-12-23 US disclosed
EP-0764269-A2 CROSSLINKED POLYACRYLAMIDE GELS WITH HIGH MONOMER: CROSSLINKER RATIOS Amresco, Inc. (US) 1997-03-26 EP disclosed
WO-1996032628-A9 CROSSLINKED POLYACRYLAMIDE GELS WITH HIGH MONOMER: CROSSLINKER RATIOS 1997-01-30 WO disclosed
WO-1996032628-A2 CROSSLINKED POLYACRYLAMIDE GELS WITH HIGH MONOMER: CROSSLINKER RATIOS AMRESCO, INC. (US) 1996-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227802-A1 ANTIBACTERIAL AMINOGLYCOSIDE DERIVATIVES ATP6V1B1, ABCB11, RPN2 MEN1 4260/4885KMT2A 4247/4885ALDH1A1 1148/4885
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 MEN1 2754/4885KMT2A 2273/4885ALDH1A1 1209/4885
US-20230023377-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF REN, PKD1, NPR1 MEN1 218/4885KMT2A 3608/4885ALDH1A1 985/4885
US-20050267134-A1 Non-nucleotide composition and method for inhibiting platelet aggregation P2RY12, P2RY11, P2RY13 MEN1 3549/4885KMT2A 4586/4885ALDH1A1 3381/4885
US-20230029252-A1 FUCOSYLATED CHONDROITIN SULFATE OLIGOSACCHARIDE, PREPARATION METHOD THEREFOR, COMPOSITION THEREOF AND USE THEREOF FUCA1, FUCA2, CSGALNACT1 MEN1 2364/4885KMT2A 3729/4885ALDH1A1 1203/4885
US-20240150367-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, NPR1 MEN1 204/4885KMT2A 3544/4885ALDH1A1 936/4885
US-20050159388-A1 Non-nucleotide compositions and method for inhibiting platelet aggregation P2RY12, P2RY11, P2RY13 MEN1 3712/4885KMT2A 4496/4885ALDH1A1 3046/4885
US-11945824-B2 Heterocyclic compounds as anti-viral agents VIP, ACE, FURIN MEN1 1492/4885KMT2A 2438/4885ALDH1A1 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.